Diane Dragaud
January 5, 2023
The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes
January 5, 2023
Adding immunotherapy to standard chemotherapy keeps most patients in remission and improves their survival
September 26, 2022
Summaries of recently reported ECOG-ACRIN research results
June 28, 2022
Reaching more women in local communities, especially women of color, will ensure that the trial results apply to all women—and move health equity forward